Skip to content

Abatacept

Orencia (abatacept) is a protein pharmaceutical. Abatacept was first approved as Orencia on 2005-12-23. It is used to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
Trade Name Orencia
Common Name Abatacept
Indication juvenile arthritis, psoriatic arthritis, rheumatoid arthritis
Drug Class Receptor molecules, native or modified: T-cells
Abatacept
Get full access now